PINK1/Parkin Activators represent a promising therapeutic approach for Parkinson's disease and other neurodegenerative disorders characterized by mitochondrial dysfunction. This page provides comprehensive information about the PINK1/Parkin pathway, therapeutic strategies, and current research progress.
| Property |
Value |
| Category |
Mitochondrial Quality Control |
| Target |
PINK1/Parkin Mitophagy Pathway |
| Diseases |
Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy |
| Stage |
Preclinical to Phase I |
The PINK1/Parkin pathway is a critical mitochondrial quality control mechanism. Loss-of-function mutations in PRKN (Parkin) and PINK1 (PTEN-induced kinase 1) genes cause early-onset familial Parkinson's disease, highlighting the therapeutic potential of activating this pathway.
- Phosphorylation of Parkin: PINK1 phosphorylates Parkin at Ser65, activating its E3 ubiquitin ligase activity
- Ubiquitin Phosphorylation: PINK1 phosphorylates ubiquitin, enhancing Parkin recruitment
- Mitochondrial Damage Sensing: Accumulation of PINK1 on damaged mitochondria triggers mitophagy
- E3 Ligase Function: Parkin ubiquitinates mitochondrial outer membrane proteins
- Autophagy Receptor Recruitment: Ubiquitin chains recruit autophagy receptors (p62, OPTN, NDP52)
- Mitochondrial Clearance: Damaged mitochondria are engulfed and degraded by lysosomes
- PINK1 Activators: Small molecules that enhance PINK1 kinase activity
- Parkin Activators: Compounds that promote Parkin recruitment and activation
- Phospho-ubiquitin Mimetics: Stabilize phosphorylated ubiquitin to enhance pathway activity
¶ Therapeutic Candidates
| Compound |
Mechanism |
Development Stage |
| Rapamycin |
mTOR inhibition, indirect mitophagy enhancement |
Preclinical |
| Nicotinamide |
NAD+ boost, SIRT1 activation |
Preclinical |
| Urolithin A |
Mitophagy induction via BET inhibition |
Phase III (gut) |
| Rapamycin analogs |
mTORC1 inhibition |
Various stages |
- PINK1-ST: Stabilized PINK1 protein fragments
- Phospho-ubiquitin variants: Engineered ubiquitin derivatives
- Parkin-binding compounds: Small molecules enhancing Parkin recruitment
- AAV-PINK1: Viral delivery of PINK1 gene
- AAV-Parkin: Gene replacement therapy
- CRISPR activation: Enhancing endogenous PINK1/Parkin expression
- Familial PD: PRKN and PINK1 mutations cause ~10% of early-onset PD
- Sporadic PD: Mitochondrial dysfunction is a hallmark of idiopathic PD
- Neuroprotection: Activation may prevent dopaminergic neuron loss
- Mitochondrial dysfunction contributes to alpha-synuclein pathology
- PINK1/Parkin activation may reduce Lewy body formation
- Oligodendroglial mitochondrial dysfunction
- Potential for neuroprotection via mitophagy enhancement
- Alzheimer's Disease: Mitochondrial abnormalities in neurons
- Huntington's Disease: Mitochondrial deficit
- Amyotrophic Lateral Sclerosis: Energy metabolism defects
- PINK1 activators protect dopaminergic neurons from mitochondrial toxins
- Parkin overexpression reduces mitochondrial dysfunction markers
- Phospho-ubiquitin enhances Parkin recruitment to damaged mitochondria
- PINK1 knockout mice show mitochondrial dysfunction
- Parkin overexpression provides neuroprotection in PD models
- Pharmacological mitophagy inducers improve motor function
PINK1/Parkin activators work synergistically with:
- Mitochondrial antioxidants: Address ROS production
- Dopamine replacement: Levodopa, DA agonists
- Anti-inflammatory agents: Reduce microglia-mediated damage
- Neurotrophic factors: Support neuron survival
- Phospho-ubiquitin: Measure pathway activation in CSF
- Mitochondrial DNA: Release from damaged mitochondria
- PINK1 levels: Peripheral blood mononuclear cells
- Parkin recruitment: Imaging in peripheral tissues
- Mitophagy flux: Live cell imaging assays
- Motor function: Unified Parkinson's Disease Rating Scale (UPDRS)
- Many PINK1/Parkin activators have poor brain penetration
- Novel delivery systems being developed (liposomes, nanoparticles)
- Off-target effects possible with broad mitophagy inducers
- Need for pathway-specific targeting
- Excessive mitophagy may be detrimental
- Balance between clearance and survival
- Direct PINK1 activators: More potent and specific compounds
- Phospho-ubiquitin analogs: Stabilized versions for enhanced activity
- Gene therapy: Long-term expression of pathway components
- Biomarker development: Patient selection and treatment response
The study of Pink1 Parkin Activators has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85(2):257-273.
- Narendra D, et al. Parkin is recruited selectively to impaired mitochondria and activates their autophagy. Curr Biol. 2010;20(12):1155-1161.
- Matsuda N, et al. PINK1 stabilized by mitochondrial membrane potential regulates parkin E3 ligase activity. Nature. 2014;514(7523):438-442.
- Kazlauskaite A, et al. Phosphorylation of parkin at Serine65 is essential for its activation. Nat Commun. 2014;5:4398.
- McWilliams TG, et al. Phosphorylation of ubiquitin as a marker of mitochondrial dysfunction. Nat Cell Biol. 2015;17(12):1607-1614.
- Ryan BJ, et al. PINK1 and parkin: mitochondrial quality control in neurodegeneration. Nat Rev Neurosci. 2018;19(8):489-502.
- Eiyama A, Okamoto K. PINK1/Parkin in neurodegeneration. J Biochem. 2015;157(6):373-381.
- Scarffe LA, et al. Parkin and PINK1: much more than mitophagy. Nat Rev Neurosci. 2014;15(10):618-635.